Skip to content

Korro Bio, Inc. (KRRO) — Institutional Holders & Catalysts | BiotechEdge

BiotechEdgeNew: AI Alerts

Catalysts Convergence Squeeze Signals Cash Runway Insiders Research

Sign In Start 14-Day Free Trial

Home›Companies›Korro Bio, Inc. (KRRO)

Korro Bio, Inc.

KRRO

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Short interest: 8.4% of float.

Share

Score Holdings Short Interest Catalysts Insiders Research

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Signal Score

4.5/10

3 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 3 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

3 fund convergence

Rock Springs Capital

Driehaus Capital

OrbiMed Advisors

Position history (shares)

Rock Springs Capital

3Q

Driehaus Capital

3Q

OrbiMed Advisors

3Q

AI Signal

Signal Note: Driehaus Exit from KRRO Despite Specialist Fund Convergence

Driehaus Capital's $32.2M exit from Korro Bio contradicts the high-conviction signal typically implied by specialist fund clustering (OrbiMed, Rock Springs also hold). This suggests either deteriorating clinical trajectory concerns for KRRO's lead program (KO-947, a DNA repair therapeutic in development), valuation misalignment, or portfolio rebalancing unrelated to fundamentals.

Unlock full AI analysis — 14-day free trial

3 quarters

Position Trend

May 15, 2025

$11.3M

3 funds

Aug 14, 2025

$8.1M

3 funds

Nov 14, 2025

$35.4M

3 funds

Feb 17, 2026

$0

0 funds

-100% total institutional value over 4 quarters

Short Interest

Short Shares

1.02M

Change

-4.5%

Days to Cover

4.4

% of Float

8.4%

Settlement

Mar 13, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ADriehaus Capital0.0%Feb 17, 2026

SC 13G/ADriehaus Capital7.2%Nov 14, 2025

SC 13GDriehaus Capital5.3%Feb 14, 2025

SC 13G/AEventide Asset Management4.2%Nov 14, 2024

SC 13GEventide Asset Management6.8%Feb 14, 2024

Position Details

Rock Springs CapitalEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

11 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

APLS2 funds ARGX2 funds PTCT2 funds MLYS2 funds CAI2 funds TERN2 funds VERA2 funds ASND2 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: